Vaccination and Covid 19 Infections

1. Coronavirus (covid-19) vaccinations. Our World in Data. https://ourworldindata.org/covid-vaccinations. Search in Google Scholar

2. CDC. Frequently asked questions about covid-19 vaccination. 25 Jan 2021. ncov/vaccines/faq.html. Search in Google Scholar

3. KFF COVID-19 Vaccine Monitor: June 2021.https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-june-2021. Search in Google Scholar

4. NIH. Lasting immunity found after recovery from COVID-19. 2021. https://www.nih.gov/newsevents/nih-research-matters/lasting-immunity-found-after-recovery-covid-19#main-content. Search in Google Scholar

5. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371:eabf4063. doi: 10.1126/science.abf4063 pmid: 33408181.10.1126/science.abf4063 Search in Google Scholar

6. Block J. Vaccinating people who have had covid-19: why doesn’t natural immunity count in the US? BMJ. 2021 Sep 13;374:n2101. doi: 10.1136/bmj.n2101. Erratum in: BMJ. 2021 Sep 15;374:n2272. PMID: 34518194.10.1136/bmj.n2101 Search in Google Scholar

7. Klausner J. Op-Ed: Quit ignoring natural covid. Medpage Today 2021 May 28. Immunity. https://www.medpagetoday.com/infectiousdisease/covid19/92836. Search in Google Scholar

8. FDA. Pfizer-BioNTech covid-19 vaccine EUA amendment review memorandum. Table 9. 2021. https://www.fda.gov/media/148542/download#page=19. Search in Google Scholar

9. Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med 2021;218:e20202617.. doi: 10.1084/jem.20202617 pmid: 33646265).10.1084/jem.20202617 Search in Google Scholar

10. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination Kentucky, May-June 2021.MMWR Morb Mortal Wkly Rep 2021;70:1081-3. doi: 10.15585/mmwr.mm7032e1 pmid: 34383732.10.15585/mmwr.mm7032e1 Search in Google Scholar

11. Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I, Misra A. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021 May-Jun;15(3):1007-1008. doi: 10.1016/j.dsx.2021.05.001. Epub 2021 May 3. PMID: 33991805; PMCID: PMC8091733.10.1016/j.dsx.2021.05.001 Search in Google Scholar

12. Jacobson KB, Pinsky BA, Montez Rath ME, Wang H, Miller JA, Skhiri M, Shepard J, Mathew R, Lee G, Bohman B, Parsonnet J, Holubar M. Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. Clin Infect Dis. 2021 Jun 17:ciab554. doi: 10.1093/cid/ciab554. Epub ahead of print. PMID: 34137815; PMCID: PMC8344553.10.1101/2021.04.14.21255431 Search in Google Scholar

13. Public health investigations of COVID-19 vaccine breakthrough cases Case investigation protocol-march 2021-CDC. Search in Google Scholar

14. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html. Access date, March 2021. Search in Google Scholar

15. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage United States, December 29, 2020January 12, 2021. MMWR Morb Mortal Wkly Rep 2021;70:9599. Search in Google Scholar

16. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA 2021. doi:10.1001/jama.2021.1612.10.1001/jama.2021.1612 Search in Google Scholar

17. Abbasi J. Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination. JAMA. 2021 Aug 3;326(5):376-377. doi: 10.1001/jama.2021.11717. PMID: 34259836.).10.1001/jama.2021.11717 Search in Google Scholar

18. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, Hu C, Selvachandran S, Antonelli M, Murray B, Canas LS, Molteni E, Graham MS, Modat M, Joshi AD, Mangino M, Hammers A, Goodman AL, Chan AT, Wolf J, Steves CJ, Valdes AM, Ourselin S, Spector TD. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Jul;21(7):939-949. doi: 10.1016/S1473-3099(21)00224-3. Epub 2021 Apr 27. PMID: 33930320; PMCID: PMC8078878.10.1016/S1473-3099(21)00224-3 Search in Google Scholar

19. Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of covid-19 vaccines: a vaccine recipient survey. Life (Basel) 2021;11:249. doi: 10.3390/life11030249 pmid: 3380301410.3390/life11030249800273833803014 Search in Google Scholar

20. Walach H, Klement RJ, Aukema W. Retracted: The Safety of COVID-19 Vaccinations-We Should Rethink the Policy. Vaccines (Basel). 2021 Jun 24;9(7):693. doi: 10.3390/vaccines9070693. Retraction in: Vaccines (Basel). 2021 Jul 02;9(7):null. PMID: 34202529; PMCID: PMC8294615)10.3390/vaccines9070729 Search in Google Scholar

21. McMorrow M. (rep.). Improving communications around vaccine breakthrough and vaccine effectiveness. 2021. Retrieved from https://context-CDC.Washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165. Search in Google Scholar

22. Cromer D, Steain M, Reynaldi A, et al. SARS-CoV-2 variants: neutralizing antibodies required for protective immunity. MedRxiv 2021 pre-print. doi: 10.1101/2021.08.11.2126187610.1101/2021.08.11.21261876 Search in Google Scholar

23. Wu K, Choi A, Koch M, et al. Preliminary analysis of safety and immunogenicity of SARS-CoV-2 variant vaccine booster. MedRxiv 2021 pre-print. doi: 10.1101/2021.05.05.21256716.10.1101/2021.05.05.21256716 Search in Google Scholar

24. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin EG, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay G. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28. PMID: 34320281; PMCID: PMC8362591.10.1056/NEJMoa2109072 Search in Google Scholar

25. Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra AB, Khal AA, Coyle PV, Kanaani ZA, Kaleeckal AH, Latif AN, Masalmani YA, Bertollini R, Raddad LJA. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. Int J Infect Dis. 2021 Sep;110:353-358. doi: 10.1016/j.ijid.2021.08.008. Epub 2021 Aug 8. PMID: 34375762; PMCID: PMC8349447.10.1016/j.ijid.2021.08.008 Search in Google Scholar

26. Pauwels K.B., Pritchard, E., Matthews, P.C. et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med (2021). https://doi.org/10.1038/s41591-021-01548-7.10.1038/s41591-021-01548-7 Search in Google Scholar

27. Bertollini R, Chemaitelly H, Yassine HM, Al-Thani MH, Al-Khal A, Abu-Raddad LJ. Associations of vaccination and of prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar.JAMA 2021;326:185-8. doi: 10.1001/jama.2021.9970 pmid: 3410620110.1001/jama.2021.9970 Search in Google Scholar

28. Hall VJ, Foulkes S, Charlett A, etalSIREN Study Group. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021;397:1459-69. doi: 10.1016/S0140-6736(21)00675-9 pmid: 3384496310.1016/S0140-6736(21)00675-9 Search in Google Scholar

29. Goldberg Y, Mandel M, Woodbridge Y, et al. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel. [Preprint.] medRxiv 2021.04.20.21255670. doi: 10.1101/2021. 04.20. 21255670 Search in Google Scholar

30. Shrestha NK, Burke PC, Niowacki AS, Terpeluk P, Gordon SM. Necessity of COVID-19 vaccination in previously infected individuals.[Preprint.] medRxiv 2021.06.01.21258176; doi: 10.1101/2021.06.01.2125817610.1101/2021.06.01.21258176 Search in Google Scholar

31. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083. doi: 10.15585/mmwr.mm7032e1. PMID: 34383732; PMCID: PMC8360277.10.15585/mmwr.mm7032e1836027734383732 Search in Google Scholar

32. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Preprint. medRxiv. 2021;2021.12.14.21267755. Published 2021 Dec 14. doi:10.1101/2021.12.14.2126775 Search in Google Scholar

33. CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) variant-United States, December 1-8, 2021. Morb Mortal Weekl Rep. 2021; 70(50):1731-1734 [PMC free article] [PubMed] [Ref list]10.15585/mmwr.mm7050e1 Search in Google Scholar

34. Ingraham NE, Ingbar DH. The omicron variant of SARS-CoV-2: Understanding the known and living with unknowns. Clin Transl Med. 2021;11(12):e685. doi:10.1002/ctm2.685.10.1002/ctm2.685 Search in Google Scholar

35. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21:939-49. doi: 10.1016/S1473-3099(21)00224-3 pmid: 33930320.10.1016/S1473-3099(21)00224-3 Search in Google Scholar

36. Cho, A., Muecksch, F., Schaefer-Babajew, D. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600, 517522 (2021). https://doi.org/10.1038/s41586-021-04060-7). Search in Google Scholar

37. Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobryzynski, D., Posavad, C. M., … DMID 21-0012 Study Group (2021). Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report. medRxiv : the preprint server for health sciences, 2021.10.10.21264827. https://doi.org/10.1101/2021.10.10.21264827) Search in Google Scholar

38. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15. PMID: 34525275; PMCID: PMC8461568.)10.1056/NEJMoa2114255 Search in Google Scholar

39. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021 Aug;27(8):1379-1384. doi: 10.1038/s41591-021-01413-7. Epub 2021 Jun 14. PMID: 34127854; PMCID: PMC8363499.10.1038/s41591-021-01413-7 Search in Google Scholar

40. Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts crossvariant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021; 25: eabg9175).10.1101/2021.02.05.21251182 Search in Google Scholar

41. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 2021 March 26 (Epub ahead of print.10.1038/s41591-021-01318-5 Search in Google Scholar

42. Thiesen H.J /CEO, IndyMed, Rostock, Germany-7xfnityquaf5h phapa2hz2r8fpx5lwxj.pdf article under press. Search in Google Scholar

43. Falsey AR, Frenck RW Jr, Walsh EE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Bailey R, Swanson KA, Xu X, Koury K, Kalina W, Cooper D, Zou J, Xie X, Xia H, Türeci Ö, Lagkadinou E, Tompkins KR, Shi PY, Jansen KU, ªahin U, Dormitzer PR, Gruber WC. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021 Oct 21;385(17):1627-1629. doi: 10.1056/NEJMc2113468. Epub 2021 Sep 15. PMID: 34525276; PMCID: PMC8461567.10.1056/NEJMc2113468 Search in Google Scholar

44. Thomas SJ, Moreira ED, Kitchin N, et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med 2021 [Submitted]. Search in Google Scholar

45. Questions and answers EU digital covid certificate. Jun 2021. https://ec.europa.eu/commission/presscorner/detail/en/QANDA_21_2781). Search in Google Scholar

46. UK Department of Health and Social Care. Who can get an NHS COVID Pass in England. 26 Aug 2021. https://www.gov.uk/guidance/nhs-covid-pass#who-canget-an-nhs-covid-pass-inengland) Search in Google Scholar

47. What is a green pass? https://corona.health.gov.il/en/directives/green-pass-info/. Search in Google Scholar

48. De Foo C, Grépin KA, Cook AR, Hsu LY, Bartos M, Singh S, Asgari N, Teo YY, Heymann DL, Legido-Quigley H. Navigating from SARS-CoV-2 elimination to endemicity in Australia, Hong Kong, New Zealand, and Singapore. Lancet. 2021 Oct 30;398(10311):1547-1551. doi: 10.1016/S0140-6736(21)02186-3. Epub 2021 Oct 4. PMID: 34619099; PMCID: PMC8489883.10.1016/S0140-6736(21)02186-3 Search in Google Scholar